Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Br J Clin Pharmacol ; 42(6): 743-6, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8971430

RESUMEN

1. The influence of food on the absorption of frusemide and bumetanide was compared in two separate randomized crossover studies. 2. On three separate occasions frusemide 40 mg was administered to eight healthy male volunteers intravenously, orally in the fasting state and orally after a standard breakfast. Blood and urine were collected at intervals over 8 h and urine alone for a further 16 h. The study was then repeated in nine healthy volunteers using intravenous and oral bumetanide 2 mg. 3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h). The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%). 4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h). However, food had no statistically significant effect on the bioavailability and urinary recovery of bumetanide. 5. In this study, the absorption of bumetanide was affected less than frusemide by food.


Asunto(s)
Bumetanida/farmacocinética , Diuréticos/farmacocinética , Interacciones Alimento-Droga , Furosemida/farmacocinética , Adulto , Área Bajo la Curva , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Humanos , Absorción Intestinal , Masculino
2.
Br J Clin Pharmacol ; 42(4): 522-4, 1996 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8904629

RESUMEN

The effects of frusemide on the urinary excretion of dopamine and 5-hydroxytryptamine (5-HT) were investigated in eight healthy male subjects in a randomized, placebo-controlled, cross-over study. Frusemide produced the expected rise in urinary dopamine excretion but it did not affect 5-HT excretion when compared with placebo. The lack of an effect on 5-HT excretion in man contrasts with studies in the rat which have reported a marked increase in 5-HT excretion after administration of this loop diuretic.


Asunto(s)
Diuréticos/orina , Dopamina/orina , Furosemida/farmacología , Serotonina/orina , Adulto , Humanos , Masculino , Placebos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...